Wastewater-based epidemiology has emerged as a game-changer for analyzing the spread of COVID-19 because it can
detect viral RNA/DNA before outbreaks start
display local trends without testing patients
reduce costs of clinical surveillance by up to US$ 1 billion
Interested in being part of the next viral breakthrough?
Want to deepen your understanding of this transformative technology?
Use the free guide below to learn how to use highly sensitive SARS-CoV-2 wastewater assays to collect, prepare, and gain insights into your sample in less than 4 hours.

Do you struggle to find new potential targets or biomarkers in your disease of interest?
Disease networks are a valuable tool for understanding disease drivers and discovering potential new molecular players. This free poster contains a machine learning (ML)-generated network that involves a set of novel and known molecular players and relevant biological functions representative of lung carcinoma, plus a detailed description of the pathway on the back of the poster.

Are you interested in finding new potential targets or biomarkers for your disease of interest?
Disease networks like this one for mesothelioma (MESO) are a valuable tool for understanding disease drivers and discovering potential new molecular players - and is one of over 1500 networks available in QIAGEN IPA.
This poster contains a machine learning (ML)-generated network that involves a set of novel and known molecular players and relevant biological functions representative of MESO, along with a detailed description on the back of the poster.

Microbes touch all aspects of our lives, from health to food production. They can also trigger various harmful or beneficial effects on us. This makes the detection and monitoring of microbes important for understanding their biological function, especially in infection or colonization of our body.
Download this free workflow for guidance on microbial detection, with a particular focus on NGS and digital PCR.

qPCR data can be highly variable due to reliance on standard curves or references to perform quantification.
As digital PCR is non-reliant on the kinetics of the PCR reaction and does not depend on standard curves, absolute quantification is enabled.
This short, 4 page application note compares the performance between these two techniques (qPCR and dPCR) focusing specifically on precision and sensitivity.

Download this collection of whitepapers to learn about advanced pathway analysis and how to unlock the power of 'omics data sets. Included in the collection:
How Advanced Pathway Analysis Leads to Impactful Biological Discoveries
Biomarker & Target Discovery with QIAGEN Digital Insights Solutions
Unlock the Power of 'Omics Datasets with QIAGEN IPA Analysis Match
Connect the Dots: Deriving Insights from Thousands of 'Omics Datasets
Top features of QIAGEN Ingenuity Pathway Analysis

qPCR data can be highly variable due to reliance on standard curves or references to perform quantification.
As digital PCR is non-reliant on the kinetics of the PCR reaction and does not depend on standard curves, absolute quantification is enabled.
This short, 4 page application note compares the performance between these two techniques (qPCR and dPCR) focusing specifically on precision and sensitivity.

Are you an MSc or PhD student researching cancer, microbiology or sustainability?
You could get a grant comprising $10k in QIAGEN consumables and a one-year CLC Workbench Premium license worth $5k.
Apply by May 15th.

If you work in cancer biomarker and target research, chances are you use data from The Cancer Genome Atlas (TCGA) to help you make discoveries. This comprehensive and coordinated effort helps accelerate our understanding of the molecular causes of cancer through genomic analyses, including large-scale genome sequencing.
Download and read our white paper to access the full details of how QIAGEN OmicSoft OncoLand helps boost TCGA exploration.
Download and use our unique and comprehensive matadata dictionary of clinical covariates to quickly discover the meaning of over 1000 relevant fields for deeper TCGA data exploration across cancers.

Next-generation sequencing (NGS) can deliver unprecedented insights.
With QIAGEN's NGS solutions, you can benefit from extensive expertise and market-leading informatics helping you to achieve:
Accurate results from even the most challenging of samples
Faster turnaround times using streamlined and optimized workflows
Meaningful insights from complex NGS data
QIAGEN's QIAseq technologies help address a number of NGS worfklow challenges. By combing the flexibility of QIAseq technology with the convenience of automation, you can turbo charge your library prep and save hours of hands-on time for larger runs.
How can using QIAseq technologies to automate your library prep help you?
Less than 20 minutes of hands-on time
Ideal for large volumes of samples
Increased reproducibility
Reduced sample handling reduces risk of contamination
Partner with QIAGEN to navigate the complexity of the NGS world with ease.

QIAGEN is Transforming the PCR Experience with Digital PCR
If your future is digital, why shouldn't your PCR be, too?
There are a number of benefits in using dPCR in your experiments, including:
Sealed nanoplates eliminate the risk of contamination
User-friendly, PCR-like plates provide a familiar workflow
Allows quicker time-to-result
Fixed partitions prevent variation in size and coalescence as seen in droplets
Imagine keeping the familiarity and ease of qPCR but gaining the higher sensitivity and precision of digital PCR, without prolonging the time to scientific insight.
The QIAcuity, QIAGEN's fully integrated nanoplate-based digital PCR system, has been designed with your research needs and the limitations of the currently available methods in mind. It's time to simplify the transition from qPCR and prepare your critical research applications for the changing landscape of digital PCR.

This PHAD network was created by using a machine-learning model in which molecules, functions and diseases are represented as embeddings encoding activating and inhibiting effects.
This network includes some of the pathological events contributing to PHAD: Muscularization of pulmonary vessels, proliferation of pulmonary arterial smooth muscle cells (PASC), induction of nitric oxide and systolic pressure of the right ventricle. The role of immune cells in inflammatory processes is also shown (generation of bone marrow-derived dendritic cells, quantity of TH2 cells, TH2 immune response and amount of CD11b+ cells, activation of eosinophils and activation of helper T lymphocytes and others) (2,3).

The lung has a relatively low rate of regular cell turnover but a high capacity for healing from injury. It contains adult stem cells, which have the ability to undergo self-renewal and to differentiate into other cell types during regeneration. These progenitor cells occur in several tissue niches and include a variety of cell types, including epithelial cells, endothelial cells and fibroblasts. Alveolar cells comprise predominantly ATI cells (alveolar epithelial type I) and their regeneration is critical to restoring normal barrier and gas exchange function. The regeneration of alveolar cells is a dynamic process, beginning with an acute inflammatory response and recruitment of immune cells. The second step is the activation of epithelial stem cells (including ATII cells) which migrate to the site of injury and then proliferate and finally differentiate into ATI cells (1–2).

Oxytocin (OT), synthesized in hypothalamic magnocellular neuroendocrine cells in the supraoptic and paraventricular nuclei, is most commonly associated with labor and lactation, but it is also implicated in a wide variety of physiological (bone formation, synaptogenesis, etc.), behavioral (social behavior, pair bonding, etc.) and pathological functions (cardioprotection, diabetes mellitus,
neuroprotection) (1–2).
The cardioprotective effect of OT is attributed to the production of cGMP and the release of protective atrial natriuretic peptide (ANP) and nitric oxide (NO). The beneficial actions of OT include an increase in glucose uptake by cardiomyocytes, reduction in cardiomyocyte
hypertrophy, decrease in oxidative stress and mitochondrial protection, increasing cellular survival (2, 6).

Scientists risk missing out on important, career-making discoveries by performing analyses with tools that do not reveal the full biological picture.
The use of standard, basic analyses performed with outdated tools and information could be detrimental to publishing in renowned journals, or to publishing at all. While once cutting edge, many simple pathway analysis tools only represent pathways as collections of genes. When analyzing your data, they fail to consider the biological relationships and causal influences the genes in a pathway have on one another, including activation, inhibition and downstream outcomes. For deeply impactful research, basic pathway analysis won't cut it.
Download this white paper and learn how to accelerate your research discoveries, and your career, with advanced pathway analysis.

Drowning in a sea of data from public repositories?
Discover a better way.
In this report, learn about the hidden costs of free data and how they delay your discoveries. Find out how to bypass the downloading, processing and curating, and start exploring the data right away.

Tumors use various means to redirect elements of the immune system to encourage proliferation and suppress immune attack. This molecular activity is illustrated in this pathway (see the back of the poster for detailed description), and in the related PD-1, PD-L1 cancer immunotherapy pathway from QIAGEN IPA (not shown).

Coronaviruses make extensive use of cellular membranes to avoid immune attack, and generate membrane-enclosed virion progeny. Viruses enter cells through endosomes after docking at the plasma membrane, but manage, with the aid of nsp6, to exit at the early endosome stage, before they encounter lysosomes. The replication proteins reside inside autophagy-derived vesicles (promoted by viral membrane proteins nsp3, nsp4 and nsp6). Virion proteins, after synthesis in the endoplasmic reticulum, are transported and assembled in endoplasmic reticulum–golgi intermediate compartments (ERGIC).

With QIAGEN IPA, virologists, as well as life science and public health lab researchers, can easily analyze interactions of host molecular mechanisms during viral infection. Built on evidence from thousands of curated publications from biomedical literature, IPA networks are constructed to predict gene and drug effects on selected biological processes, diseases or pathways.
IPA can analyze differential expression profiles to identify impacted functions, pathways in viral infection datasets, generate hypotheses about novel regulatory networks and gain additional insights about single-cell biology.

Analyzing large transcriptomics or proteomics datasets typically involves answering two broad questions regarding the set of differentially-expressed genes or proteins: 1) What does the data reveal about the underlying biology in the sampled cells or tissues; and 2) What relevance does that biological information have with respect to other biological samples? We want to understand whether the phenomenon is unusual or commonplace, and whether there are informative similarities to other areas of biology.
Ingenuity Pathway Analysis (IPA®) was created to answer the first question and Analysis Match was created within IPA to answer the second.

To help you get a head start in your research, we are providing four NGS research grants worth $20,000 each. Next-generation sequencing (NGS) technology has revolutionized the scientific research landscape, fueling discovery and enabling unprecedented insights in diverse applications.
Simply take a 5-minute survey by August 31 to share your NGS applications and challenges with us, and you could be selected to receive a QIAGEN NGS research grant. Research grant awardees can select up to $20,000 of QIAseq NGS products, with 16 hours of Field Application Specialist support to kick off their project.
Four grant recipients will be selected, so sign up soon!

GeneGlobe streamlines the complete research cycle of target exploration, product configuration, data analysis and follow-up experiment planning – with just one tool. Join our free webinar series and learn how your research can benefit.
Afterwards, you can participate in our fun quiz with a chance to win a poster featuring your favorite signaling pathway.
Part 1: Plan your next experiment using GeneGlobe: streamlining a breast cancer research planning workflow
July 8, 2020 at 8 am CEST / 2 am EDT and 6 pm CEST / 12 pm EDT
Dr. Verena Schramm, Associate Director, GeneGlobe
Good planning is key to research success, but limited time and resources can make this difficult. In this webinar, we will show you how to use GeneGlobe to streamline an example breast cancer research planning workflow. We will guide you through the GeneGlobe functionalities and show how to leverage the knowledge hub with >10,000 manually-curated biological entities. We will demonstrate how to explore biological targets in their relevant scientific context and find the right research products to study them from our broad catalog of PCR, NGS and functional tools in just a few clicks. We will also show how to store targets of interest in the My GeneGlobe project space and use these target lists to build custom products using one of our user-friendly custom builders.
Part 2: Setting the new standard in mRNA/lncRNA qPCR expression analysis: introducing the QuantiNova LNA PCR systems
July 15, 2020 at 8 am CEST / 2 am EDT and 6 pm CEST / 12 pm EDT
Marie-Louise Lunn, Ph.D., Associate Director, Gene Expression
Assays Product Management QIAGEN has enhanced its mRNA/lncRNA profiling assays and panels with LNA technology and optimized with QuantiNova chemistry to create a comprehensive new portfolio for highly sensitive and specific gene expression analysis. These two new PCR systems are available through GeneGlobe and offer the choice of SYBR® Green or hydrolysis probe-based detection with the broadest coverage of predesigned human, mouse and rat assays and panels. For specialized applications, researchers can easily create custom assays and panels. In this webinar, we will discuss the principles behind the design and high performance of these new LNA-enhanced assays and show how they are setting a new standard in mRNA/lncRNA qPCR expression analysis.
Part 3: QuantiNova LNA PCR data analysis software to complete your gene expression analysis
July 22, 2020 at 3 am CEST / 9 am EDT and 1 pm CEST / 7 pm EDT
George J. Quellhorst, Jr., Ph.D., Associate Director in R&D
No experiment is complete without processing and interpreting the data. This webinar demonstrates the benefits of using the free and easy-to-use GeneGlobe QuantiNova LNA PCR data analysis software to perform this final step. See how the software first interprets the built-in quality control assays and helps determine the best normalization method. From there, the software calculates fold change results and their statistical significance using the standard DDCT method and Student’s t-test. Choose from several available plots to visualize the results in publication-quality images. Also, use the software to design the best follow-up experiments. Identify the PCR assays needed to perform an even more focused gene expression analysis or to analyze the expression and/or function of miRNAs predicted to regulate the observed differentially expressed genes. Finally, export the results in an Excel file and/or a PDF report suitable for presentation purposes.

Join the online webinar!
Part 1: We explore a new workflow for simultaneous NGS profiling of both DNA variants and RNA fusions, as well as gene expression in just one day, using as little as 10 ng sample.
We’ll discuss:
Challenges of having two separate workflows on overall and hands-on time and cost
How to maximize the information you derive from a single sample in half the time
QIAseq Multimodal Panel overview and sample capabilities
How SPE-based technology ensures greater coverage, while Unique Molecular Index (UMI) technology enables high-sensitivity detection of DNA variants and RNA fusions
Performance data review
Part 2: We will take you through an introduction and live demo of the QIAGEN CLC Genomics Workbench workflow for multimodal analysis. Discover this intuitive yet powerful solution tailored for analysis of NGS data generated with QIAseq Multimodal Panels.
REGISTER NOW
Wed, Feb 12, 2020 5:00 PM - 6:00 PM CET
Wed, Feb 19, 2020 5:00 PM - 6:00 PM CET

The new QIAGEN Cancer Research Community is for dedicated and passionate cancer researchers. We are working to conquer cancer with an emphasis on collaborating together worldwide to share knowledge, materials, methods and data to enable breakthroughs in cancer research.
Get exclusive access to our first Cancer Insights Sessions.
Sign up for our first activities and be part of the new QIAGEN Cancer Research Community from the beginning – learn about the value of multimodality approaches in liquid biopsy analysis and how to get a more complete picture of liquid biopsies by analyzing circulating tumor cells, extracellular vesicles and cell-free DNA in parallel.
Podcasts by Corinna Keup and Siegfried Hauch
1. RNA Profiles of Circulating Tumor Cells and Extracellular Vesicles
2. Targeted Deep Sequencing Revealed Variants in Fell-free DNA of Hormone Receptor-Positive Metastatic Breast Cancer Patients
3. Cell-Free DNA Variant Sequencing Using CTC-Depleted Blood for Comprehensive Liquid Biopsy Testing in Metastatic Breast Cancer
Science Talks
1. Molecular Analysis Research of Circulating Tumor Cells, Extracellular Vesicles and Nucleic Acids in Liquid Biopsies – Sabine Kasimir-Bauer joined by Siegfried Hauch, Constanze Kindler and Markus Sprenger-Haussels
2. mRNA Profiling of Matched CTCs and EVs: an Example for Synergy – Corinna Keup joined by Siegfried Hauch, Constanze Kindler and Martin Schlumpberger
3. ccfDNA Targeted Deep Sequencing: New Insights into Clinical Relevance of Liquid Biopsies – Corinna Keup joined by Siegfried Hauch and Markus Storbeck
4. ccfDNA Variants and Matched CTC mRNA Profiles: Is that Possible from One Blood Tube? – Corinna Keup joined by Siegfried Hauch, Sabine Kasimir-Bauer, Markus Storbeck and Constanze Kindler
5. QIAGEN R&D experts in liquid biopsy analysis will discuss findings and answer your questions in a live webcast talk show to round off the first Cancer Insight Sessions. Look forward to this event in February.

A single, 10-second step can change the outcome of your RNA-seq.
Struggling to achieve consistent gene expression reads? Ribosomal RNA (rRNA) could be to blame, wasting valuable sequencing resources and jeopardizing your ability to detect low-abundance mRNA transcripts. rRNA contamination is especially critical when performing RNA-seq with FFPE and degraded low-yield RNA samples.
You don’t have to settle for sub-optimal RNA-seq results. There’s a better way: The QIAseq FastSelect way.
Read the story of Dr. Fabienne Desmots-Loyer at the CHU - Hospital Pontchaillou – find out how QIAseq FastSelect saved the day by providing high-quality libraries from paired patient follicular lymphoma FFPE tumor samples previously rejected for processing by two commercial labs due to high levels of RNA degradation and low yields.
Read the full story